The Myotubular Trust’s Research Strategy is to fund proof of principle translational research projects that will significantly advance and speed up the search to find a cure and/or a treatment for any of the genetic forms of centronuclear and myotubular myopathy.
We are delighted to announce that Myotubular Trust and the renowned children’s medical research charity, Action Medical Research, are teaming up to fund a project grant in 2018 for translational research into myotubular and centronuclear myopathy. Applications must meet the remit of both charities and all outline applications will be judged in open competition on both potential clinical impact, and scientific quality.
Applications may be made for project grants of up to 3 years in duration up to £200,000 per award. Up to £200,000 of joint funding is available to spend on these co-funded projects in 2018. Principal investigators and applicants must be based at UK institutions and awards can only be made to UK institutions. Researchers outside the UK can collaborate on UK based projects if appropriate.
The application process will be managed through the Action Medical Research 2018 grant round and the outline application form can be found here. Successful applicants from the outline stage will then be invited to complete a full application for full external peer review in open competition with other applications in the Action Medical Research grant round.
The Myotubular Trust (Registered Charity No: 1137177) was set up in 2006 to raise money for research to find a cure and / or treatment for myotubular myopathy.
There are three genetically distinct forms of Myotubular Myopathy. The commonest is x-linked, affecting only boys, and also the most severe. It usually presents in the newborn period and there are associated breathing and swallowing difficulties in addition to the general muscle weakness. The other forms are either dominant or recessive in inheritance, are usually milder and vary widely.
Over the last few years, we have awarded research grants / fellowships for the following projects:
• Gene therapy for x-linked myotubular myopathy and pathophysiology – Dr Anna Buj Bello, Genethon, Evry - £102,290 over 2 years
• Membrane trafficking and T tubule structure and function in a canine model of centronuclear myopathies – Dr Richard Piercy, Royal Veterinary College, London - £38,548 over 3 years
• Deciphering the molecular pathway involving centronuclear myopathy genes – Manuela D’Alessandro, IGBMC, Illkirch - £120,000 over 3 years
• Gene therapy for autosomal dominant centronuclear myopathy by Transplicing – Dr Marc Bitoun, INSERM, Paris - £102,340 over 2 years
• Next generation sequencing to tackle centronuclear myopathies – Dr Jocelyn Laporte, IGBMC, France - £62,000 over 2 years
• Secondary pathogenic mechanisms in XLMTM and CNM – Dr Susan Treves, Basel University Hospital, Basel and Dr Heinz Jungbluth, King’s College London - £116,664 over 3 years
• Pre-clinical gene replacement therapy for X-Linked myotubular myopathy – Dr Anna Buj Bello, Genethon, Evry - £110,300 over 2 years
• Reducing DNM2 as a novel therapeutic target for centronuclear myopathy – Dr Jocelyn Laporte, IGBMC, France - £132,000 over 3 years
• PI3 Kinase Inhibition as a Novel Treatment Strategy for MTM –Dr James, Dowling, Hospital for Sick Children, Toronto, Canada - £102,500 over 2 years
• Myotubular and Centronuclear Myopathy Patient Registry curation –TREAT-NMD team based at the John Walton Muscular Dystrophy Research Centre at Newcastle University - £40,744 over 2 years
The Myotubular Trust has a Scientific Board which is chaired by Professor Francesco Muntoni of The Institute of Child Health, University College London. The Board makes recommendations to the Myotubular Trust trustees on which projects to fund.
We are holding a seventh call for research projects. We will require completed applications by 1700 hours GMT Wednesday 30th November 2016. We anticipate making awards in May / June 2017.
We are proud to have a relationship with Sparks the children’s medical research charity, who as a much larger funder with a grant administration team, are able to provide the Myotubular Trust with grant management services. Sparks is a member of the Association of Medical Research Charities (AMRC) – a membership organisation of the leading medical and health research charities in the UK.
Both Myotubular Trust and Sparks are committed to only funding high quality research grants that have been through a robust peer review process. Sparks holds an ARMC Certificate of Best Practice in Medical Research and Health Research Peer Review.
We are looking to fund further projects that will help find a cure and / or a treatment for any of the three types of myotubular myopathy (congenital X-linked recessive; congenital autosomal recessive; autosomal dominant), focusing on research that would not generally be funded by public or industrial funding sources. This call will be open to international applications.
Applications may be made for:
1. Project grants. We will consider applications from the Principal Investigator for projects of 2-3 years duration to be carried out by a Post Doctoral researcher, or PHD student
2. A Myotubular Trust fellowship, non-clinical. Applicants will have identified a host institution and will be undertaking a basic science project of 3-4 years duration
In particular we would like to encourage the application of new technologies to research into myotubular myopathy, which may involve collaboration between different medical disciplines and / or different research institutions. We are also willing to consider applications which involve joint funding with other organisations.
Please download an application forms in either PDF or Word Document here:
Should you have any questions relating to this call for projects, please email email@example.com.
Please feel free to download the pdf explaining more about the Myotubular Trust's research selection process.